Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

Insulet (PODD) saw the biggest growth in the S&P 500 healthcare index, rising about 25% as it continues to gain market share in the type 1 diabetes market. Eli Lilly (LLY) came in second ...